LT3236972T - Antivirusiniai n4-hidroksicitidino dariniai - Google Patents

Antivirusiniai n4-hidroksicitidino dariniai

Info

Publication number
LT3236972T
LT3236972T LTEPPCT/US2015/066144T LT15066144T LT3236972T LT 3236972 T LT3236972 T LT 3236972T LT 15066144 T LT15066144 T LT 15066144T LT 3236972 T LT3236972 T LT 3236972T
Authority
LT
Lithuania
Prior art keywords
hydroxicitidine
antiviral
derivatives
hydroxicitidine derivatives
Prior art date
Application number
LTEPPCT/US2015/066144T
Other languages
English (en)
Inventor
George R. Painter
David B. Guthrie
Gregory R. Bluemling
Michael G. Natchus
Original Assignee
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56151433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT3236972(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Emory University filed Critical Emory University
Publication of LT3236972T publication Critical patent/LT3236972T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/067Pyrimidine radicals with ribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/073Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • C07H19/10Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEPPCT/US2015/066144T 2014-12-26 2015-12-16 Antivirusiniai n4-hidroksicitidino dariniai LT3236972T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462096915P 2014-12-26 2014-12-26
US201562201140P 2015-08-05 2015-08-05
PCT/US2015/066144 WO2016106050A1 (en) 2014-12-26 2015-12-16 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Publications (1)

Publication Number Publication Date
LT3236972T true LT3236972T (lt) 2021-11-10

Family

ID=56151433

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEPPCT/US2015/066144T LT3236972T (lt) 2014-12-26 2015-12-16 Antivirusiniai n4-hidroksicitidino dariniai

Country Status (23)

Country Link
US (3) US20190022116A1 (lt)
EP (2) EP3939985B1 (lt)
JP (4) JP7381190B2 (lt)
KR (2) KR20170123308A (lt)
CN (2) CN118286245A (lt)
AU (3) AU2015370004B2 (lt)
BR (1) BR112017013858A2 (lt)
CA (1) CA2972259A1 (lt)
CY (1) CY1124663T1 (lt)
DK (1) DK3236972T3 (lt)
EA (1) EA201791460A1 (lt)
ES (1) ES2892123T3 (lt)
HR (1) HRP20211456T1 (lt)
HU (1) HUE056470T2 (lt)
IL (3) IL296496B2 (lt)
LT (1) LT3236972T (lt)
PL (1) PL3236972T3 (lt)
PT (1) PT3236972T (lt)
RS (1) RS62434B1 (lt)
SG (2) SG10202105371YA (lt)
SI (1) SI3236972T1 (lt)
SM (1) SMT202100592T1 (lt)
WO (1) WO2016106050A1 (lt)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202105371YA (en) * 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
EP3506909B1 (en) 2016-09-02 2022-06-29 Dicerna Pharmaceuticals, Inc. 4'-phosphate analogs and oligonucleotides comprising the same
JP7016170B2 (ja) * 2016-12-16 2022-02-04 国立大学法人東海国立大学機構 ヌクレオシド誘導体及びその利用
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
FI3706762T3 (fi) * 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
CN108586294A (zh) * 2018-05-29 2018-09-28 王若锴 一种脲类衍生物及其在防治炎症中的应用
KR102783030B1 (ko) * 2019-02-01 2025-03-18 재단법인 경기도경제과학진흥원 중동호흡기증후군 치료 또는 예방용 약학 조성물
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
CN115666587A (zh) * 2020-02-07 2023-01-31 埃默里大学 N4-羟基胞苷和衍生物及其相关的抗病毒用途
CN111548384B (zh) * 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药
EP4125989A4 (en) * 2020-04-03 2024-05-29 Selva Therapeutics, Inc. VIRAL ENTRY INHIBITORS AND RNA POLYMERASE INHIBITORS
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
CN116264827A (zh) * 2020-07-24 2023-06-16 加利福尼亚大学董事会 抗病毒前药、药物制剂和方法
US11702440B2 (en) * 2020-12-10 2023-07-18 Optimus Drugs Private Limited Pharmaceutical polymorphs of Molnupiravir
CN114621229B (zh) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
MX2023007241A (es) * 2020-12-18 2023-06-29 Merck Sharp & Dohme Llc Sintesis de nucleosidos antivirales.
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112939981B (zh) * 2021-01-19 2022-08-26 嘉兴金派特生物科技有限公司 核苷化合物、药学上可接受的盐、组合物及其应用
WO2022159787A1 (en) * 2021-01-22 2022-07-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for the treatment of a disease or disorder, methods for identifying said compounds
AU2022253068A1 (en) * 2021-04-09 2023-10-26 Emory University Thionucleosides as antiviral agents
US11407779B1 (en) 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
CA3219218A1 (en) * 2021-05-06 2022-11-10 Council Of Scientific And Industrial Research A process for the preparation of n4-hydroxycytidine and its derivatives
WO2022251663A2 (en) * 2021-05-27 2022-12-01 Emory University Novel universal anti-rna virus agents
CN117642410A (zh) * 2021-06-18 2024-03-01 苏州春海生物医药有限公司 N4-羟基胞苷的酯衍生物及其用途
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
JP2024528237A (ja) 2021-08-06 2024-07-26 インターベット インターナショナル ベー. フェー. 獣医学的ウイルス性疾患の治療方法
WO2023025319A1 (zh) * 2021-08-27 2023-03-02 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
CN113980074A (zh) * 2021-10-21 2022-01-28 苏州立新制药有限公司 N4-羟基胞苷的晶型a与制备方法和用途
WO2023073239A1 (en) 2021-11-01 2023-05-04 Immunic Ag Medical use of n4-hydroxy citicoline compounds
CN116583530A (zh) * 2021-11-12 2023-08-11 苏州春海生物医药有限公司 N4-羟基胞苷的酯衍生物及其用途
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116496334A (zh) * 2022-01-25 2023-07-28 上海和誉生物医药科技有限公司 一种抗病毒抑制剂及其在药学上的应用
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
TW202348228A (zh) 2022-02-24 2023-12-16 德商艾斯巴赫生物有限公司 病毒組合療法
WO2023167488A1 (ko) * 2022-03-02 2023-09-07 유재혁 몰누피라비르의 국소 투여용 수의학적 조성물 및 그 이용
KR102917091B1 (ko) * 2022-03-02 2026-01-23 유재혁 몰누피라비르의 국소 투여용 수의학적 조성물 및 그 이용
CN116731087A (zh) * 2022-03-03 2023-09-12 上海科胜药物研发有限公司 一种莫那比拉韦及其中间体的制备方法
KR20230130898A (ko) * 2022-03-04 2023-09-12 동아대학교 산학협력단 N4-이소부티릴옥시시티딘 모방체 합성과 이의 항바이러스 용도를 포함하는 바이러스 감염 치료용 조성물
CN114573651A (zh) * 2022-03-11 2022-06-03 山东大学 一种n4-羟基胞苷脂质前药及其制备方法与应用
JP2025509635A (ja) 2022-03-15 2025-04-11 ローム・セラピューティクス・インコーポレイテッド 疾患を治療するための化合物及び方法
CN114805458B (zh) * 2022-03-31 2023-09-08 中国人民解放军军事科学院军事医学研究院 类核苷广谱抗病毒药物的脂肪酸前药及其制备方法和用途
WO2024123207A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение
WO2024123206A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина

Family Cites Families (283)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325798A (en) 1970-09-24 1973-08-08 Upjohn Co Derivatives of 2,2-anhydro-ara-cytidine
GB1386334A (en) 1972-09-22 1975-03-05 Kohjin Co 2,2-cyclocytidine derivatives
FR2252851B1 (lt) 1973-11-29 1978-07-21 Kohjin Co
US4096324A (en) 1975-07-07 1978-06-20 The Upjohn Company Cytidine nucleoside compound
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US5968914A (en) * 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
CA2058632C (en) 1989-06-05 2004-08-24 Brian C. Froehler Exonuclease-resistant oligonucleotides and methods for preparing the same
AU9094991A (en) 1990-11-23 1992-06-25 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU6632094A (en) 1993-04-19 1994-11-08 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
KR100386685B1 (ko) 1993-09-17 2003-12-31 길리애드 사이언시즈, 인코포레이티드 뉴클레오타이드동족체류
WO1995007920A1 (en) 1993-09-17 1995-03-23 Gilead Sciences, Inc. Nucleotide analogs
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
AU743333B2 (en) 1996-10-21 2002-01-24 Gilead Sciences, Inc. Piperidine compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
FR2776289B1 (fr) 1998-03-20 2001-02-02 Oreal Composition de teinture d'oxydation contenant un coupleur cationique, procedes de teinture, nouveaux coupleurs cationiques
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
JP5230052B2 (ja) 2000-05-26 2013-07-10 イデニクス(ケイマン)リミテツド フラビウイルスおよびペスチウイルス治療のための方法および組成物
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
ATE491459T1 (de) 2000-10-18 2011-01-15 Pharmasset Inc Modifizierte nukleoside zur behandlung von virusinfektionen und abnormaler zellulärer proliferation
CA2743451A1 (en) 2000-10-18 2002-04-25 Pharmasset, Inc. Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
US20030124512A1 (en) 2000-10-18 2003-07-03 Lieven Stuyver Simultaneous quantification of nucleic acids in diseased cells
PL209031B1 (pl) 2001-04-30 2011-07-29 Trommsdorff Arzneimittel Estry urydyny, ich zastosowanie i sposób wytwarzania, oraz kompozycje farmaceutyczne je zawierające
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
WO2003090691A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
SG165996A1 (en) 2002-07-15 2010-11-29 Gilead Sciences Inc Combination therapies with l-fmau for the treatment of hepatitis b virus infection
JPWO2004024185A1 (ja) 2002-09-11 2006-01-26 道男 石橋 医薬または化粧料
WO2004031224A2 (en) 2002-10-01 2004-04-15 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
AU2003301439A1 (en) 2002-10-16 2004-05-04 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
AU2003287606A1 (en) * 2002-11-12 2004-06-03 Enzon Pharmaceuticals, Inc. Novel acylating reagents
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP1581496A4 (en) 2002-12-02 2008-04-23 Gilead Sciences Inc 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
WO2004100960A2 (en) 2003-04-25 2004-11-25 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
CA2523083C (en) 2003-04-25 2014-07-08 Gilead Sciences, Inc. Antiviral phosphonate analogs
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
NZ544988A (en) 2003-07-30 2009-11-27 Gilead Sciences Inc Nucleobase phosphonate analogs for antiviral treatment
ATE433974T1 (de) 2003-09-19 2009-07-15 Gilead Sciences Inc Azachinolinolphosphonatverbindungen als integraseinhibitoren
RU2264409C2 (ru) * 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург
US7273717B2 (en) 2003-10-24 2007-09-25 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds with GS-9005 ester hydrolase B
WO2005049633A1 (en) 2003-11-03 2005-06-02 Cognis Ip Management Gmbh Acyl ribonucleosides and acyl deoxyribonucleosides
JP4970048B2 (ja) 2003-12-22 2012-07-04 カトリーケ・ウニフェルジテイト・ルーベン・カー・イュー・ルーベン・アール・アンド・ディ イミダゾ[4,5−c]ピリジン化合物および抗ウイルス治療の方法
JP2007515495A (ja) 2003-12-22 2007-06-14 ギリアード サイエンシーズ, インコーポレイテッド 4’−置換カルボビル誘導体およびアバカビル誘導体ならびにhivおよびhcv抗ウイルス活性を有する関連化合物
ES2389602T3 (es) 2003-12-30 2012-10-29 Gilead Sciences, Inc. Fosfonatos de nucleósidos y análogos de los mismos para el tratamiento de infecciones por el VPH
US20050282839A1 (en) 2004-01-12 2005-12-22 Gilead Sciences, Inc. Pyrimidyl phosphonate antiviral compounds and methods of use
AU2005209256B2 (en) 2004-01-21 2010-11-18 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
PL1742642T3 (pl) 2004-04-14 2009-06-30 Gilead Sciences Inc Analogi fosfonianowe związków inhibitorów integrazy HIV
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
PT1778702E (pt) 2004-07-16 2011-10-18 Gilead Sciences Inc Compostos antivirais
PL216369B1 (pl) 2004-07-27 2014-03-31 Gilead Sciences Pochodne fosfonianowe, kompozycje farmaceutyczne zawierające te pochodne oraz zastosowanie tych pochodnych do wytwarzania leku do hamowania wirusa HIV
CN101027303A (zh) 2004-07-27 2007-08-29 吉里德科学公司 咪唑并[4,5-d]嘧啶类、其应用和制备方法
DE102004051804A1 (de) * 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
JP2008518024A (ja) 2004-10-26 2008-05-29 ギリアード サイエンシーズ, インコーポレイテッド ミコフェノール酸のホスホネート誘導体
DE602005013580D1 (de) 2004-12-21 2009-05-07 Leuven K U Res & Dev Imidazoä4,5-cüpyridinverbindung und verfahren zur antiviralen behandlung
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
US8686045B2 (en) 2005-06-08 2014-04-01 The University Of North Carolina At Chapel Hill Methods of facilitating neural cell survival using non-peptide and peptide BDNF neurotrophin mimetics
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
WO2007014174A2 (en) 2005-07-25 2007-02-01 Gilead Sciences, Inc. Drug-resistant mutants of hepatitis c virus
JP2009502964A (ja) 2005-07-27 2009-01-29 ギリアード サイエンシーズ, インコーポレイテッド Hivを阻害するための抗ウイルス性ホスホン酸結合体
CA2619049A1 (en) 2005-08-16 2007-02-22 Irm, Llc Compounds and compositions as protein kinase inhibitors
DE602006003913D1 (de) 2005-09-22 2009-01-08 Hoffmann La Roche Selektive o-acylierung von nukleosiden
AP2702A (en) 2005-12-30 2013-07-23 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
HRP20140626A2 (hr) 2006-03-29 2014-11-07 Gilead Sciences, Inc. Postupak priprave inhibitora proteaze hiv
US20090318456A1 (en) 2006-07-06 2009-12-24 Gilead Sciences, Inc. Substituted pteridines for the treatment and prevention of viral infections
TWI360549B (en) 2006-07-07 2012-03-21 Gilead Sciences Inc Novel pyridazine compound and use thereof
PT2049506E (pt) 2006-07-07 2015-10-09 Gilead Sciences Inc Moduladores de propriedades farmacocinéticas de agentes terapêuticos
ES2437871T3 (es) 2006-07-07 2014-01-14 Gilead Sciences, Inc. Moduladores del receptor tipo toll 7
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
US8673929B2 (en) 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
EP2049547A2 (en) 2006-07-21 2009-04-22 Gilead Sciences, Inc. Aza-peptide protease inhibitors
CA2657936C (en) 2006-07-21 2017-01-10 Gilead Sciences, Inc. Antiviral protease inhibitors
BRPI0714880A2 (pt) 2006-07-24 2013-05-21 Gilead Sciences Inc inibidores da transcriptase reversa do hiv
AU2007277253A1 (en) 2006-07-24 2008-01-31 Gilead Sciences, Inc. Bisfuranyl protease inhibitors
CA2664156A1 (en) 2006-09-27 2008-04-03 Coley Pharmaceutical Group, Inc. Compositions of tlr ligands and antivirals
CA2672298C (en) 2006-12-14 2015-02-03 K.U.Leuven Research & Development Fused pyridine compounds useful in the prophylaxis or treatment of viral infections
WO2008077650A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
BRPI0807581A2 (pt) 2007-02-23 2014-07-01 Gilead Science, Inc. Moduladores de propriedades farmacocinéticas de produtos terapêuticos
CA2682638C (en) 2007-03-29 2012-07-17 F. Hoffmann-La Roche Ag Pharmaceutical composition comprising (2r, 3s, 4r, 5r)-5-(4-amino-2-oxo-2h-pyrimidin-1-yl)-2-azido-3,4-bis-iso-butyryloxy-tetrahydro-furan-2-ylmethyl isobutyrate
CN101743004A (zh) 2007-06-29 2010-06-16 吉里德科学公司 治疗用组合物及其用途
CA2692145C (en) 2007-06-29 2015-03-03 Gilead Sciences, Inc. Antiviral compounds
NZ582086A (en) 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 hiv 역전사효소 억제제
TWI395746B (zh) 2007-06-29 2013-05-11 Gilead Sciences Inc 抗病毒性化合物
JP5395068B2 (ja) 2007-06-29 2014-01-22 ギリアード サイエンシーズ, インコーポレイテッド トール様受容体7の調節物質としてのプリン誘導体およびその使用
WO2009005690A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
EA200971115A1 (ru) 2007-06-29 2010-04-30 Корея Рисерч Инститьют Оф Кемикал Текнолоджи Новые ингибиторы обратной транскриптазы вич
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
UA99308C2 (ru) 2007-09-26 2012-08-10 Маунт Синай Скул Оф Медсин Аналог азацитидина и его применение
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
JP2011508740A (ja) * 2007-12-27 2011-03-17 エピファニー バイオサイエンシズ, インク. 抗ウイルス化合物
ES2555209T3 (es) 2008-01-04 2015-12-29 Gilead Sciences, Inc. Inhibidores del citocromo P450
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
AU2009240630B2 (en) 2008-04-23 2013-07-18 Gilead Sciences, Inc. Carba-nucleoside analogs for antiviral treatment
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
US8536187B2 (en) 2008-07-03 2013-09-17 Gilead Sciences, Inc. 2,4,6-trisubstituted pyrido(3,2-d)pyrimidines useful for treating viral infections
JP5620376B2 (ja) 2008-07-08 2014-11-05 ギリアード サイエンシーズ, インコーポレイテッド Hiv阻害剤化合物の塩
TW201016698A (en) 2008-07-25 2010-05-01 Gilead Sciences Inc Antiviral compounds
WO2010077613A1 (en) 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
UY32325A (es) 2008-12-19 2010-07-30 Gilead Sciences Inc Inhibidores de ns3 proteasa del vhc
AU2009330333A1 (en) 2008-12-22 2011-07-07 Gilead Sciences, Inc. Antiviral compounds
PE20161067A1 (es) 2009-02-10 2016-10-23 Gilead Sciences Inc Analogos carba-nucleosidicos para tratamiento antiviral
KR20180028070A (ko) 2009-05-13 2018-03-15 길리애드 파마셋 엘엘씨 항바이러스 화합물
TWI598358B (zh) * 2009-05-20 2017-09-11 基利法瑪席特有限責任公司 核苷磷醯胺
WO2010151488A1 (en) 2009-06-23 2010-12-29 Gilead Sciences, Inc. Combination of boceprevir with 5- ( { 6- [2, 4- bis (trifluoromethyl) phenyl] pyridazin-3 -yl } methyl) -2- (2 -fluorophenyl) -5h- imidazo [4, 5-c] pyridine for the treatment of hcv
TW201111381A (en) 2009-06-23 2011-04-01 Gilead Sciences Inc Pharmaceutical combinations useful for treating HCV
TW201113279A (en) 2009-06-23 2011-04-16 Gilead Sciences Inc Pharmaceutical compositions useful for treating HCV
US8999969B2 (en) 2009-07-09 2015-04-07 Gilead Sciences, Inc. Anti-RSV compounds
AU2010276441B2 (en) 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
EP2507249B1 (en) 2009-09-09 2015-11-11 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
BR122021021135B1 (pt) 2009-09-21 2022-08-30 Gilead Sciences, Inc Compostos análogos de 2-flúor substituído carba-nucleosídeo, composição farmacêutica e uso dos compostos análogos de 2´-flúoro substituído carbonucleosídeo
CN102666541B (zh) 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
WO2011079016A1 (en) 2009-12-22 2011-06-30 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
AU2011205744B2 (en) 2010-01-15 2015-06-25 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
PT2523951E (pt) 2010-01-15 2015-09-14 Gilead Sciences Inc Inibidores de vírus flaviviridae
MX337050B (es) 2010-01-28 2016-02-10 Riboscience Llc Compuestos 4'-azido-nucleósidos como anti-vhc.
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20130005678A1 (en) * 2010-03-30 2013-01-03 Clavis Pharma Asa Methods and Compositions for Treating or Ameliorating Cancer Using Gemcitabine-5'-Elaidate
JP5807058B2 (ja) 2010-05-10 2015-11-10 ギリアード サイエンシーズ, インコーポレイテッド 二機能キノリン誘導体
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2571882A1 (en) 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
US20110306541A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Methods for treating hcv
CA2800670C (en) 2010-06-11 2020-02-18 Gilead Sciences, Inc. Topical antiviral formulations
US8722041B2 (en) * 2010-06-16 2014-05-13 Governors Of The University Of Alberta Anti-human equilibrative nucleoside transporter 1 (hENT1) antibodies and methods of use thereof
RS54761B1 (sr) 2010-06-24 2016-10-31 Gilead Sciences Pirazolo[1,5-a]pirimidini i-triazini kao antiviralni agensi
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SG186821A1 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc 2 -quinolinyl- acetic acid derivatives as hiv antiviral compounds
WO2012012465A1 (en) 2010-07-19 2012-01-26 Clarke, Michael, O'neil Hanrahan Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
PH12013500035A1 (en) 2010-07-22 2013-03-11 Gilead Sciences Inc Methods and compounds for treating paramyxoviridae virus infections
CN102351931B (zh) * 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
TW201305185A (zh) 2010-09-13 2013-02-01 Gilead Sciences Inc 用於抗病毒治療之2’-氟取代之碳-核苷類似物
WO2012039791A1 (en) 2010-09-20 2012-03-29 Gilead Sciences, Inc. 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment
AU2011328980B2 (en) 2010-11-17 2015-07-30 Gilead Sciences, Inc. Antiviral compounds
NZ610729A (en) 2010-11-19 2015-10-30 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine hcl and tenofovir disoproxil fumarate
UY33775A (es) 2010-12-10 2012-07-31 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae, composiciones farmacéuticas que los comprenden y sus usos
WO2012087596A1 (en) 2010-12-20 2012-06-28 Gilead Sciences, Inc. Combinations for treating hcv
WO2012088178A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
US20130280212A1 (en) 2010-12-21 2013-10-24 Gilead Sciences, Inc Inhibitors of cytochrome p450
US8987313B2 (en) 2010-12-21 2015-03-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
JP2014511859A (ja) 2011-04-04 2014-05-19 ギリアード サイエンシーズ, インコーポレイテッド Hivインテグラーゼ阻害剤の調製のためのプロセス
CA2830845A1 (en) 2011-04-04 2012-10-11 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
WO2012142523A2 (en) 2011-04-13 2012-10-18 Gilead Sciences, Inc. 1'-substituted pyrimidine n-nucleoside analogs for antiviral treatment
SG194512A1 (en) 2011-04-21 2013-12-30 Gilead Sciences Inc Benzothiazole compounds and their pharmaceutical use
JP2014513123A (ja) 2011-05-02 2014-05-29 ギリアード サイエンシーズ, インコーポレイテッド 無定形固体の塩
EP2729489A1 (en) 2011-07-06 2014-05-14 Gilead Sciences, Inc. Hcv genotype 3 replicons
ES2553449T3 (es) 2011-07-06 2015-12-09 Gilead Sciences, Inc. Compuestos para el tratamiento de VIH
WO2013006721A1 (en) 2011-07-06 2013-01-10 Gilead Sciences, Inc. Hcv genotype 4 replicons
EP2734515B1 (en) 2011-07-13 2015-11-04 Gilead Sciences, Inc. Thiophen-2-carboxylic acid derivatives useful as inhibitors of flaviviridae viruses
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
AU2012308295B2 (en) 2011-09-16 2017-10-26 Gilead Sciences, Inc. Methods for treating HCV
WO2013066748A1 (en) 2011-10-31 2013-05-10 Gilead Pharmasset Llc Methods and compositions for treating hepatitis c virus
DK2907816T3 (en) 2011-11-16 2018-09-24 Gilead Pharmasset Llc CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS
EP3777867A1 (en) 2011-11-29 2021-02-17 Gilead Pharmasset LLC Composition and methods for treating hepatitis c virus
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
WO2013090929A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
JP2015504881A (ja) 2011-12-20 2015-02-16 ギリアード サイエンシーズ, インコーポレイテッド 胃腸感染および障害を処置するための医薬組成物および方法
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ, インコーポレイテッド 抗ウイルス剤としてのピラゾロ[1,5−a]ピリミジン
SG10201610936RA (en) * 2011-12-22 2017-02-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2013103738A1 (en) 2012-01-04 2013-07-11 Gilead Sciences, Inc. Napthalene acetic acid derivatives against hiv infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
CA2860995A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2013115916A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections
MD20140091A2 (ro) 2012-02-03 2015-01-31 Gilead Sciences, Inc. Terapie combinată cuprinzând hemifumarat tenofovir alafenamidă şi cobicistat pentru utilizare în tratamentul infecţiilor virale
AU2013232378B2 (en) 2012-03-13 2017-09-28 Gilead Sciences, Inc. 2'- substituted carba-nucleoside analogs for antiviral treatment
CN104203253A (zh) * 2012-03-21 2014-12-10 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
CN106986869A (zh) 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
CN105121418A (zh) 2012-04-20 2015-12-02 吉利德科学公司 苯并噻唑-6-基乙酸衍生物及其治疗hiv感染的用途
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
NZ724503A (en) 2012-06-08 2017-12-22 Gilead Sciences Inc Macrocyclic inhibitors of flaviviridae viruses
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
CA2875718A1 (en) 2012-06-08 2013-12-12 Selcia Limited Macrocyclic inhibitors of flaviviridae viruses
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
US20140094485A1 (en) 2012-10-03 2014-04-03 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
WO2014064588A2 (en) 2012-10-26 2014-05-01 Koninklijke Philips N.V. Autostereoscopic display device having a see-through mode of operation.
RU2015119999A (ru) * 2012-10-29 2016-12-20 Кокристал Фарма, Инк. Пиримидиновые нуклеозиды и их монофосфатные пролекарства для лечения вырусных инфекций и рака
MX2015005448A (es) 2012-10-30 2015-11-06 Gilead Sciences Inc Metodos de terapia y diagnostico relacionados con lisil oxidasa-tipo 2 (loxl2).
WO2014074620A1 (en) 2012-11-07 2014-05-15 Gilead Sciences, Inc. Hcv genotype 6 replicons
US9211300B2 (en) 2012-12-19 2015-12-15 Idenix Pharmaceuticals Llc 4′-fluoro nucleosides for the treatment of HCV
CN110684067A (zh) 2012-12-21 2020-01-14 艾丽奥斯生物制药有限公司 取代的核苷和核苷酸
SI2822954T1 (sl) 2012-12-21 2016-07-29 Gilead Sciences, Inc. Policiklične karbamoilpiridonske spojine in njihova farmacevtska uporaba
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
JP5941598B2 (ja) 2013-01-09 2016-06-29 ギリアード サイエンシーズ, インコーポレイテッド 5員ヘテロアリールおよびそれらの抗ウイルス剤としての使用
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9012441B2 (en) 2013-01-09 2015-04-21 Gilead Sciences, Inc. Therapeutic compounds
WO2014124430A1 (en) * 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
TWI706945B (zh) 2013-03-01 2020-10-11 美商基利科學股份有限公司 供治療反轉錄病毒科病毒感染之治療性化合物
US20140273023A1 (en) * 2013-03-15 2014-09-18 Saladax Biomedical Inc. Gemcitabine immunoassay
CN105073758B (zh) 2013-03-15 2017-08-11 吉利德科学公司 丙型肝炎病毒抑制剂
US9187515B2 (en) 2013-04-01 2015-11-17 Idenix Pharmaceuticals Llc 2′,4′-fluoro nucleosides for the treatment of HCV
WO2014169278A1 (en) * 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv
MY186547A (en) 2013-05-16 2021-07-26 Riboscience Llc 4?-fluoro-2?-methyl substituted nucleoside derivatives
US9815864B2 (en) 2013-06-26 2017-11-14 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
WO2015023893A1 (en) 2013-08-16 2015-02-19 Gilead Sciences, Inc. Hcv genotype 4d replicons
EP3043803B1 (en) 2013-09-11 2022-04-27 Emory University Nucleotide and nucleoside compositions and their uses
AU2014331863C1 (en) 2013-10-11 2019-05-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
WO2015100144A1 (en) 2013-12-23 2015-07-02 Gilead Sciences, Inc. Crystalline forms of a macrocyclic hcv ns3 inhibiting tripeptide
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
US9463194B2 (en) 2014-02-05 2016-10-11 Gilead Sciences, Inc. Methods of treating patients co-infected with HIV and tuberculosis
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015130964A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Therapeutic compounds
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
ES2686352T3 (es) 2014-06-12 2018-10-17 Gilead Sciences, Inc. Compuestos antivíricos
CA2952018A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
JP6455995B2 (ja) 2014-06-13 2019-01-23 ギリアード サイエンシーズ, インコーポレイテッド ホスファチジルイノシトール3−キナーゼ阻害剤
US9499523B2 (en) 2014-06-13 2016-11-22 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952037A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
CA2952025A1 (en) 2014-06-13 2015-12-17 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
AU2015280234B2 (en) 2014-06-24 2021-04-01 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
CN117379452A (zh) 2014-06-24 2024-01-12 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸和其类似物
CN105288635A (zh) 2014-06-26 2016-02-03 昆明积大制药股份有限公司 一种含有阿糖胞苷5’-0-氨基酸酯的药物组合物
EP4140485A1 (en) 2014-07-11 2023-03-01 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並[3,2-d]嘧啶、呋喃並[3,2-d]嘧啶及吡咯並[3,2-d]嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 2’-氯胺基嘧啶酮及嘧啶二酮核苷類
AU2015308907B2 (en) 2014-08-29 2018-10-18 Gilead Sciences, Inc. Antiretroviral agents
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6356919B2 (ja) 2014-12-24 2018-07-11 ギリアード サイエンシーズ, インコーポレイテッド Hivの処置のためのイソキノリン化合物
AU2015371255B2 (en) 2014-12-24 2018-09-27 Gilead Sciences, Inc. Fused pyrimidine compounds for the treatment of HIV
SG10202105371YA (en) 2014-12-26 2021-07-29 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
PL3097102T3 (pl) 2015-03-04 2018-04-30 Gilead Sciences Inc Związki 4,6-diamino-pirydo[3,2-d]pirymidyny modulujące działanie receptora toll-podobnego
WO2016161382A1 (en) 2015-04-02 2016-10-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
AU2016250099A1 (en) 2015-04-14 2017-10-12 Gilead Sciences, Inc. Methods of treating hepatitis B virus
EP3294732B1 (en) 2015-05-15 2019-09-25 Gilead Sciences, Inc. Benzimidazole and imadazopyridine carboximidamide compounds having activity as inhibitors of indoleamine 2,3-dioxygenase
JP2018524308A (ja) 2015-06-17 2018-08-30 ギリアード サイエンシーズ, インコーポレイテッド テノホビルアラフェナミドの共結晶、塩および結晶形態
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
EA201792592A1 (ru) 2015-06-30 2018-06-29 Джилид Сайэнс, Инк. Фармацевтические препараты, содержащие тенофовир и эмтрицитабин
KR102630013B1 (ko) 2015-08-06 2024-01-25 키메릭스 인크. 항바이러스제로서 유용한 피롤로피리미딘 뉴클레오시드 및 그의 유사체
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017040896A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
HK1257270A1 (zh) 2015-09-15 2019-10-18 Gilead Sciences, Inc. 用於治療hiv的toll樣受體(tlr)調節劑
SG10202109869XA (en) 2015-09-16 2021-10-28 Gilead Sciences Inc Methods for treating arenaviridae and coronaviridae virus infections
ES2797900T3 (es) 2015-09-30 2020-12-04 Gilead Sciences Inc Compuestos y combinaciones para el tratamiento del VIH
TW201725044A (zh) 2015-10-01 2017-07-16 基利科學股份有限公司 用於治療癌症之btk抑制劑及查核點抑制劑之組合
PE20181207A1 (es) 2015-11-09 2018-07-23 Gilead Sciences Inc Composiciones terapeuticas para el tratamiento del virus de inmunodeficiencia humana
MA44077A (fr) 2015-12-15 2021-05-05 Gilead Sciences Inc Anticorps neutralisants le virus de l'immunodéficience humaine
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
WO2017156380A1 (en) 2016-03-10 2017-09-14 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
PT3377637T (pt) 2016-04-08 2020-06-17 Krystal Biotech Inc Composições para uso em métodos para o tratamento de ferimentos, transtornos e doenças da pele
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
ES2969239T3 (es) 2016-05-27 2024-05-17 Gilead Sciences Inc Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
WO2017223020A1 (en) 2016-06-20 2017-12-28 Merck Sharp & Dohme Corp. Cyclic phosphate substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
FI3706762T3 (fi) 2017-12-07 2024-12-13 Univ Emory N4-hydroksisytidiini ja johdannaisia sekä niihin liittyviä virusten vastaisia käyttötapoja
US20210308168A1 (en) 2018-03-07 2021-10-07 Emory University 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto
CN115666587A (zh) * 2020-02-07 2023-01-31 埃默里大学 N4-羟基胞苷和衍生物及其相关的抗病毒用途

Also Published As

Publication number Publication date
EP3939985A1 (en) 2022-01-19
IL296496B2 (en) 2024-10-01
IL279663A (en) 2021-03-01
AU2021203840C1 (en) 2024-01-25
AU2015370004A1 (en) 2017-07-13
EA201791460A1 (ru) 2017-12-29
HRP20211456T1 (hr) 2021-12-24
EP3236972A4 (en) 2019-01-23
IL279663B2 (en) 2023-02-01
CN107427529A (zh) 2017-12-01
SG11201705069YA (en) 2017-07-28
JP2022058363A (ja) 2022-04-12
EP3939985B1 (en) 2024-05-08
US11628181B2 (en) 2023-04-18
AU2021203840B2 (en) 2023-08-24
IL279663B (en) 2022-10-01
US20190022116A1 (en) 2019-01-24
HUE056470T2 (hu) 2022-02-28
CY1124663T1 (el) 2022-07-22
JP2025098020A (ja) 2025-07-01
JP2018500354A (ja) 2018-01-11
IL252997B (en) 2021-01-31
RS62434B1 (sr) 2021-11-30
ES2892123T3 (es) 2022-02-02
AU2015370004B2 (en) 2021-03-11
US20210060050A1 (en) 2021-03-04
EP3236972A1 (en) 2017-11-01
KR20230130175A (ko) 2023-09-11
BR112017013858A2 (pt) 2018-02-27
US20230293566A1 (en) 2023-09-21
DK3236972T3 (en) 2021-10-04
WO2016106050A1 (en) 2016-06-30
PL3236972T3 (pl) 2022-03-07
KR20170123308A (ko) 2017-11-07
CA2972259A1 (en) 2016-06-30
IL296496B1 (en) 2024-06-01
US12551497B2 (en) 2026-02-17
IL252997A0 (en) 2017-08-31
PT3236972T (pt) 2021-09-24
AU2023270335B2 (en) 2025-09-11
AU2021203840A1 (en) 2021-07-08
JP7381190B2 (ja) 2023-11-15
SI3236972T1 (sl) 2021-12-31
IL296496A (en) 2022-11-01
CN118286245A (zh) 2024-07-05
EP3236972B1 (en) 2021-07-28
JP2023153865A (ja) 2023-10-18
SMT202100592T1 (it) 2021-11-12
AU2023270335A1 (en) 2023-12-14
SG10202105371YA (en) 2021-07-29

Similar Documents

Publication Publication Date Title
LT3236972T (lt) Antivirusiniai n4-hidroksicitidino dariniai
DK3319956T3 (da) Substituerede oxopyridinderivater
EP3360001A4 (en) HEAD-MOUNTED DISPLAY DEVICE
DK3134402T3 (da) 4-amino-imidazoquinolinforbindelser
DK3006072T3 (da) Karadgang
DK3211743T3 (da) Ø-til-netværk-omskiftningsfremgangsmåde
LT3204359T (lt) Tetrahidroizochinolino dariniai
DK3222714T3 (da) Phytasemutanter
PL3865480T3 (pl) Pochodne hydrazyny
EP3230438C0 (en) N-GLYCOSYLATION
EP3337164A4 (en) HEAD-MOUNTED DISPLAY
HUE048321T2 (hu) Karabazol származékok
LT3402792T (lt) Chinolin-2-ono dariniai
DK3231803T3 (da) Dihydroindolizinonderivat
EP4011484C0 (en) CARBONIC ANHYDRASE OF THERMOVIBRIO AMMONIFICANS
DK4242916T3 (da) Forstøver
LT3457851T (lt) Sobetiromo dariniai
DK3183340T3 (da) Termolabile exonukleaser
LT3371168T (lt) Indolin-2-ono dariniai
DE112015001664A5 (de) Betätigungsaktuator
DK3131898T3 (da) Fluoroalkylfluorenderivativer
DK3154703T3 (da) Fuldkappe-snekkecentrifuge
DK3154689T3 (da) Komplekser
DE112015005041A5 (de) Gargerätevorrichtung
DK3110439T3 (da) Pcsk9-vacciner